News

Axentis Pharma has received the orphan drug designation for its lead product candidate Fluidosomes-tobramycin from the Office of Orphan Products Development of the FDA. According to Axentis, this

SXC Health Solutions, a provider of pharmacy benefit management services and healthcare information technology solutions, has implemented the Sterling Business Integration Suite from Sterling Commerce, to create a

Mr O’Holla has an extensive background in the fields of R&D, quality, policy development and compliance, which uniquely position him for the dynamic needs of Nfocus and its

Allergan has reported net earnings attributable to shareholders of $44.7 million, or $0.15 per share, for the quarter ended March 31, 2009, compared to $107.7 million, or $0.35

The overall objective of this grant is to generate tools useful in applying ACTCellerate technology to the manufacture of patient-specific therapeutic products. The new grant funds awarded by

According to I-Flow, this patent covers intellectual property for the infusion apparatus used in the company’s flagship ON-Q Pain Relief System and is also used as the basis

The notice of allowance is the US Patent and Trademark Office’s (USPTO’s) official communication that the examination of the patent application has been successfully completed and that a

The use of a vitamin A analog called 4-HPR, or fenretinide, in combination with certain other drugs, or ‘partnering agents’, is reportedly showing promise for selectively killing certain

Fiscal 2009 Outlook Saxelby concluded, “I am very pleased with the progress we’ve made in the first half of fiscal 2009. Landauer’s performance demonstrates the success of our